GRO Biosciences
Latest round
- Series B
Last raised
- Jul 2024
Total raised
- $58M
Investors
- 11
About GRO Biosciences
Founded in 2016, GRO Biosciences, Inc. is headquartered in Cambridge, US, and focuses on the development of protein therapeutics. The company was co-founded by Dan Mandell and Marc Lajoie, who have backgrounds in biotechnology.GRO Biosciences specializes in innovative protein therapeutics, leveraging its GRO platform to provide access to a comprehensive array of non-standard amino acids (NSAAs). This platform significantly enhances the potency, immunogenicity, and stability of therapeutic proteins. One of its key products is ProGly™, which features pre-glycosylated amino acids designed for precise glycan composition control, addressing complex health issues like autoimmune disorders.GRO Biosciences generates revenue through B2B partnerships with pharmaceutical companies, focusing on the development and commercialization of novel protein therapeutics. The company plans to broaden its pipeline and enhance its genomically recoded organism platform to facilitate scalable manufacturing of therapeutics based on non-standard amino acids.
Who invested in GRO Biosciences
11 investors across 4 rounds
See all investors in GRO Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about GRO Biosciences
Who invested in GRO Biosciences?
GRO Biosciences has 11 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has GRO Biosciences raised?
GRO Biosciences has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did GRO Biosciences last raise money?
GRO Biosciences's most recent round on record is a Series B, in Jul 2024.
What does GRO Biosciences do?
Founded in 2016, GRO Biosciences, Inc.
Where is GRO Biosciences headquartered?
GRO Biosciences is headquartered in Cambridge, US.
Which VCs invest in companies like GRO Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at GRO Biosciences's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like GRO Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.